ArticleBMC nephrology2025
The protective effect of curcumin nanoparticles on renal damage caused by a combination of bleomycin, etoposide, and cisplatin.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aryl Hydrocarbon Receptor (AhR) and Vascular Endothelial Growth Factor (VEGF) Crosstalk in Doxorubicin Nephrotoxicity: Mechanisms and Therapeutic Perspectives.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBleomycin, etoposide, and platinum (BEP) are among the most commonly used and effective anticancer medications in oncology clinics. The study's objective was to examine the efficacy of curcumin and curcumin-cyclodextrin (nanocurcumin) as protective agents against BEP nephrotoxicity.
methodsRenal toxicity was evaluated through various parameters, such as histopathology and serum urea and creatinine levels. In addition, the levels of Nitric Oxide (NO) and total antioxidant capacity (TAC) and the expression of the Tumor Necrosis Factor-alpha (TNF-α) and caspase 3 genes were investigated. These experiments were performed on Wistar rats, which were divided into six groups: control, BEP, curcumin, nanocurcumin, curcumin + BEP, and nanocurcumin + BEP.
resultsThe findings of the present study revealed that the administration of curcumin and nanocurcumin improved the blood urea and creatinine levels and improved kidney histology in rats treated with BEP. In addition, curcumin and nanocurcumin strengthened the antioxidant status in the kidney by increasing TAC and decreasing NO levels. Therefore, alterations in the gene expression of TNF-α and caspase3 showed that curcumin could modulate and regulate the process of apoptosis and inflammation caused by BEP.
conclusionsThese results showed that curcumin protects kidneys from BEP-induced toxicity by reducing oxidative stress, cell death, and inflammation, and it can be considered a possible option to improve renal complications caused by the BEP chemotherapy regimen. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.